Phio Pharmaceuticals shares are trading higher after the company announced the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals announced the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This announcement led to a rise in the company's share prices.
October 11, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals' shares are trading higher after the company announced the presentation of two key preclinical studies of its INTASYL compound PH-894.
The announcement of the presentation of two key preclinical studies of Phio Pharmaceuticals' INTASYL compound PH-894 at a major international conference has led to increased investor confidence, resulting in a rise in the company's share prices.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100